To the full analysis
Generate Biomedicines stock: growth
GENBGenerate Biomedicines reported $31.89M in revenue for fiscal 2025, up 55.9% on the prior year.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
55.9%
per year from 2024 to 2025, per share 296.7%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2024 | |
|---|---|
| Revenue | 55.9% |
| Revenue per share | 296.7% |
| Earnings | no data |
| Earnings per share | no data |
| Free cash flow | no data |
| Free cash flow per share | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2024 | $20.46M | −$173.77M | −$121.2M |
| 2025 | $31.89M | −$203.15M | −$204.13M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.